Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma-Reference-Cited by-同舟云学术

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

Published:2018-08-06 Issue:24 Volume:24 Page:6150-6159
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Kelly Kevin R.,Friedberg Jonathan W.,Park Steven I.,McDonagh Kevin,Hayslip John,Persky Daniel,Ruan Jia,Puvvada Soham,Rosen Peter,Iyer Swaminathan Padmanabhan,Stefanovic Alexandra,Bernstein Steven H.,Weitman Steven,Karnad Anand,Monohan Gregory,VanderWalde Ari,Mena Raul,Schmelz Monika,Spier Catherine,Groshen Susan,Venkatakrishnan Karthik,Zhou Xiaofei,Sheldon-Waniga Emily,Leonard E. Jane,Mahadevan Daruka

Funder

Takeda Pharmaceuticals U.S.A. (TPUSA)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Knowledge mapping of AURKA in Oncology：An advanced Bibliometric analysis (1998–2023);Heliyon;2024-06

2. Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA;Annals of Medicine;2024-05-13

3. Ageing microenvironment mediates lymphocyte carcinogenesis and lymphoma drug resistance: From mechanisms to clinical therapy (Review);International Journal of Oncology;2024-05-10

4. Frequency of Complete Remission With R-CHOP Therapy in Patients With Diffuse Large B Cell Lymphoma;Cureus;2024-04-01

5. The two sides of chromosomal instability: drivers and brakes in cancer;Signal Transduction and Targeted Therapy;2024-03-29